Gold(I) complexes of the type [AuL{κC-2-C₆H₄P(S)Ph₂}] [L = PTA, PPh₃, PPh₂(C₆H₄-3-SO₃Na) and PPh₂(2-py)]: Synthesis,...

Four new mononuclear gold (I) compounds of the type [AuL{κC-2-C₆H₄P(S)Ph₂}] {L = PTA (1), PPh₃ (2), PPh₂(C₆H₄-3-SO₃Na) (3), and PPh₂(2-py) (4)} were prepared by scission of the dinuclear compound [Au₂{μ-2-C₆H₄P(S)Ph₂}₂] by L or via a transmetalation reaction using the organotin reagent 2-Me₃SnC₆H₄P(S)Ph₂ and a suitable gold halide precursor. The cytotoxic potential of complexes 1-4 was evaluated against four human cancer cell lines of diverse cellular origin: cervical (HeLa), prostate (PC-3), non-small cell lung adenocarcinoma (A549), and fibrosarcoma (HT-1080). The in vitro cytotoxicity results showed that 1 demonstrated exceptional anticancer activity with IC₅₀ values ranging from 0.08 to 3.5 μM. Complex 3, which contains a sulfonated triphenyl phosphine ligand, displayed the weakest anticancer activity with IC₅₀ values ranging from 3.1 to >50 μM. When compared to the standard chemotherapeutic drug cisplatin, 1 displayed approximately 27-fold greater cytotoxic activity against cervical cancer cells and 3.5- and 7.5-fold greater activities against prostate and fibrosarcoma cancer cells, respectively. Additionally, 1 exhibited 3-fold selectivity for cervical cancer cells compared to non-cancerous HEK-293 cells. Mechanistic investigations revealed that 1 induced apoptosis, which was associated with elevated reactive oxygen species (ROS) and inhibition of the intracellular enzyme thioredoxin reductase. Furthermore, 1 exhibited notable antiangiogenic characteristics in an in vivo model using transgenic zebrafish Tg(fli1a:EGFP). In vivo studies using mouse xenograft models showed that complex 1 displayed superior inhibition of tumour growth (82 %) compared to the clinical drug cisplatin (29 %). Overall, these results highlight the potential of gold (I) compounds as novel antitumour agents.